

RELISA® anti-dsDNA TEST SYSTEM

For in vitro Diagnostic Use

For Professional Use

Catalog numbers: 7096-17 (96 wells) and 7696-17 (576 wells)

INTENDED USE: *This is an enzyme immunoassay test system for the detection of antibodies to dsDNA in human serum. This test system is to be used as an aid in the diagnosis of systemic lupus erythematosus.*

SUMMARY AND EXPLANATION OF THE TEST

Patients with systemic lupus erythematosus (SLE) may produce antibodies to a variety of nuclear antigens, but antibodies directed against Sm (Smith antigen) and double stranded DNA (dsDNA) show the highest correlation with disease (1). Antibodies directed against Sm demonstrate a speckled ANA staining pattern while antibodies directed against dsDNA generally demonstrate a homogeneous ANA staining pattern. Although low levels of anti-dsDNA antibodies may be present in the serum of patients with rheumatoid arthritis, Sjögren's syndrome, progressive systemic sclerosis, dermatomyositis, discoid lupus erythematosus, and mixed connective tissue disease (2), high levels of dsDNA antibodies are seen almost exclusively in SLE. Antibodies against dsDNA are thought to be involved in the pathogenesis of the most severe variants of SLE when deposited as immune complexes (3). Antibodies to dsDNA occur in high titer, and, because they correlate with disease activity (4), their detection is important in the management of SLE patients.

Several assays are available for the detection of anti-dsDNA antibodies. The most commonly used methods include indirect immunofluorescence, radioimmunoassay, counterimmunoelectrophoresis, and immunodiffusion (5-8). The Immuno Concepts RELISA® anti-dsDNA test system is an enzyme immunoassay (EIA) method that detects serum antibodies to dsDNA.

PRINCIPLE OF THE TEST

This test is an indirect EIA. Stabilized dsDNA antigens have been coated onto the surface of the microwells to serve as an antigenic substrate in this system. Dilutions of the patient samples are placed in the microwells and incubated, allowing specific antibodies in the sample to react with the antigen on the solid phase. After washing to remove unbound antibody and other serum proteins, the wells are incubated with goat anti-human antibodies that are labeled with horseradish peroxidase. The horseradish peroxidase-conjugated antibody preparation that is included in the test system is specific for human IgG gamma chains.

After incubation with horseradish peroxidase conjugate, a stable three part complex is formed if results are positive. This complex consists of horseradish peroxidase-conjugated anti-human antibody bound to human antibodies to dsDNA, which are bound to the antigen stabilized on the plastic surface.

After another washing step, this complex is detected by adding a solution of tetramethylbenzidine (TMB) and H₂O₂ as a chromogenic substrate. The degree of color development in each well is proportional to the concentration of antibodies to dsDNA in each serum sample. Each microwell is read in a spectrophotometer at 450 nm.

SYSTEM COMPONENTS - MATERIALS PROVIDED

Storage: All components should be stored under refrigeration between 2-10°C. Do not freeze.



Stability: All components remain stable at least 12 months from date of manufacture. Do not use any component beyond its expiration date.



REACTIVE REAGENTS

dsDNA coated microwell strips **PLATE**: Catalog No. 7008-17. A microwell frame containing twelve eight well strips coated with dsDNA. If fewer than eight wells are needed for testing, the wells can be separated by snapping them apart. The unused strips can be returned to the foil pouch with the desiccant pack, sealed with the zipper seal, and refrigerated for up to 45 days.

Sample Diluent **SOLN|DIL**: Catalog number 7100 (100 ml). Proprietary buffered sample diluent used to dilute patient samples.

Enzyme Antibody Reagent - Human IgG gamma chain specific **CONJ|HRP**: Catalog number 7009-17 (14 ml). Anti-human IgG (gamma chain specific) conjugated to horseradish peroxidase (HRP). Reagent is ready to use.

Substrate Solution **SOLN|SUB**   : Catalog number 7035 (14 ml). HRP-specific enzyme substrate solution, containing stabilized 3,3',5,5'-tetramethylbenzidine (TMB) and hydrogen peroxide (H₂O₂). Reagent is ready to use. **DANGER:** Flammable. This reagent contains less than 25% of methanol and acetone. Keep out of the reach of children. In case of contact with eyes, flush immediately and thoroughly with water and consult a physician.

Stopping Reagent **SOLN|STOP**   : Catalog number 7033 (14 ml). Proprietary stopping reagent for Immuno Concepts EIA test systems. Reagent is ready to use. **DANGER:** Corrosive. This reagent contains hydrochloric and sulfuric acids (less than 3% each, by volume), and should be handled with care. Keep out of the reach of children. In case of contact with eyes, flush immediately and thoroughly with water and consult a physician. Never add water to this reagent.

Anti-dsDNA Positive Control **CONTROL|+**: Catalog number 7021-17 (2 ml). Human positive control serum that contains antibodies to dsDNA. This serum is at working dilution and is ready to use. See vial label for expected range in International Units/ml (IU/ml).

Negative Control **CONTROL|-**: Catalog number 7031 (2 ml). Human negative control serum that does not contain antibodies to dsDNA. This serum is at working dilution and is ready to use.

Anti-dsDNA Calibrator Sera 1 through 4 **CAL**: Catalog numbers 7261-17, 7262-17, 7263-17, 7264-17, (1.5 ml each). Human calibrator sera that contain antibodies to dsDNA. These calibrator sera are at working dilution and are ready to use. Calibrator 3 can be used as a single point calibrator. These calibrator sera have been tested with the WHO reference preparation Wo80 to determine the antibody concentration in International Units/ml (IU/ml). See vial labels for anti-dsDNA antibody concentrations in IU/ml.

NON-REACTIVE COMPONENTS

Holder for microwells

Wash Buffer Solution:

PBS Buffer **PWDR|PBS**: Catalog No. 1011. Phosphate-buffered saline powder (0.01 M, pH 7.4 ± 0.2). Each pouch contains sufficient buffer powder to make one liter. (Two pouches of buffer powder are supplied for each 96-microwell plate in complete test kits)

Wash Buffer Concentrate **SOLN|WASH**: Catalog No. 1031 (10 ml). 5% Tween 20 solution to be used in the wash buffer. (Two vials of buffer concentrate are supplied for each 96-microwell plate in complete test kits).

Preparation: Dissolve one pouch of buffer powder in one liter of deionized or distilled water. Add the entire contents of one bottle of Wash Buffer Concentrate to the dissolved PBS. Mix well and store between 2-25°C for up to 4 weeks or until signs of contamination or other visible changes occur. Wash buffer solution must be at room temperature (18-25°C) before use.

Use: All components come ready to use with no aliquoting or reconstitution required (except the PBS buffer which must be dissolved in deionized or distilled water before use).

Stability: All components remain stable at least 12 months from date of manufacture. Do not use any component beyond its expiration date.

ADDITIONAL MATERIALS REQUIRED - BUT NOT PROVIDED

Volumetric precision pipettors to deliver 25-1000 µl volumes

Squeeze bottle for delivering wash buffer solution to microwells, or an automated or semi-automated wash system for microwells

One-liter container for PBS wash buffer solution

Deionized or distilled water

Plate reading spectrophotometer capable of reading absorbance at 450 nm

Test tubes to prepare serum dilutions

Bibulous paper or paper towels

Multichannel pipettor capable of delivering to 8 wells

Disposable gloves

Lab timer

PRECAUTIONS

1. All human source materials used for this product have been tested and found to be negative (not repeatedly reactive) for antibodies to Human Immunodeficiency Virus-1 (HIV-1), Human Immunodeficiency Virus-2 (HIV-2), hepatitis C virus (HCV), and for hepatitis B surface antigen (HBsAg) by FDA approved methods. However, no test method can offer complete assurance that HIV-1, HIV-2, hepatitis C, hepatitis B, or other infectious agents are absent. Thus, all kit materials should be handled in the same manner as potentially infectious materials.
2. All patient samples should be handled at the Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the Centers for Disease Control/National Institutes of Health Manual: *Biosafety in Microbiological and Biomedical Laboratories, 1999 Edition*.
3. Dilution of the components or substitution of components other than those provided in this system may yield inconsistent results.
4. Sodium azide (0.09%) is used as a preservative. Sodium azide may react with lead or copper plumbing and form explosive metal azide salts. When disposing of reagents, flush with ample volumes of tap water to prevent potential residues in plumbing. Sodium azide is a poison and may be toxic if ingested.
5. This kit is for *in vitro* diagnostic use.
6. Never pipette by mouth and avoid contact of reagents and specimens with skin and mucous membranes. If contact occurs, wash with a germicidal soap and copious amounts of water.
7. Do not smoke, eat, or drink in areas where specimens or kit reagents are handled.
8. Avoid splashing or generation of aerosols at all times.
9. Incubation times and temperatures other than those specified may give erroneous results.
10. Cross contamination of reagents or samples may give false results. Samples must remain confined to microwells during testing.
11. Reusable glassware must be washed and thoroughly rinsed free of detergents prior to use. All glassware must be clean and dry before use.
12. Bring all reagents, microwells, and specimens to room temperature (18-25°C) prior to use.
13. Wear disposable gloves when handling specimens and reagents, and wash hands thoroughly afterwards.
14. Microbial contamination of reagents or samples may give false results.
15. The stopping reagent is corrosive, and may cause burns. This reagent contains hydrochloric and sulfuric acids (less than 3% each by volume), and should be handled with care. Keep out of the reach of children. In case of contact with eyes, flush immediately and thoroughly with water and consult a physician. Never add water to this reagent.

SPECIMEN COLLECTION

Collection: Serum is the preferred specimen. Approximately 5 ml of whole blood should be collected aseptically by venipuncture using a sterile vacuum collection tube or other suitable collection system. Allow blood to clot at room temperature (18-25°C). Serum should be separated from the clot by centrifugation as soon as possible to minimize hemolysis.

Interfering Substances: Sera exhibiting a high degree of hemolysis, icterus, lipemia, or microbial growth should not be used because these conditions may cause false results. Specimens containing visible particulate matter should be clarified by centrifugation before testing.

Storage: Sera may be stored at 2-10°C up to one week. If testing is further delayed, sera should be stored frozen at –20°C or lower. Serum should not be stored in a self-defrosting refrigerator or freezer.

CAUTION: Repeated freeze/thawing of patient samples may yield false positive or false negative results.

GENERAL PROCEDURAL NOTES

1. It is extremely important to have all kit components and serum samples at room temperature (18-25°C) before use. A full liter of wash buffer may require several hours to warm to 20°C after removal from the refrigerator. Incubation temperatures above or below the stated range may cause inaccurate results. Return unused samples and reagents to refrigerated storage after use.
2. Mix reagents well before use by gentle inversion. Do not vortex or shake reagents. Avoid foaming.
3. When preparing sample dilutions, pipette tips should be wiped prior to dispensing serum into specimen diluent. Excess sample adhering to the outside of the pipette tip will affect results.
4. The use of a multichannel pipettor is recommended because it provides more uniform reagent dispensing, incubation times, and reaction times.
5. **Adequate washing of wells is extremely important.** Inadequately washed wells will exhibit high background values, and may show false positive values. For manual washing, aspirate the contents of the wells, then fill each well with wash buffer solution. Avoid cross-contamination of the wells, particularly in the first wash after aspiration. Drain all of the wash buffer from the wells by inverting, then shaking residual wash buffer from the wells with a sharp “snapping” motion of the wrist. Repeat the filling and draining steps for a total of 3 to 5 washes. The wells should then be rapped vigorously on a paper towel or other absorbent material to remove all traces of residual wash buffer. The use of an automated microwell washing system will assure consistent washing of the wells, and is recommended.
NOTE: Due to the various types of wash techniques and automated systems, the number of washes may be adjusted to obtain optimal results. Each laboratory should determine the most efficient number of washes for its washing system.
6. Inadequate removal of residual wash buffer can cause inconsistent color development. Microwell strips should be blotted on absorbent paper or towels to minimize residual wash buffer.
7. Timing of all steps is critical. All serum samples should be diluted before beginning the procedure, and they must be dispensed into the microwells in as short a period of time as possible (not more than five minutes). Batch sizes should be set so that specimen handling can be accomplished comfortably within this time period. The use of a multichannel pipettor facilitates the handling of samples and reagents, and is recommended.
8. With the exception of the last incubation (substrate solution), the start of each incubation period begins with completion of sample or reagent dispensing. The substrate solution incubation must be exactly 30 minutes for each well. All samples and reagents should be dispensed in the same sequence and at a constant rate.

INTERPRETATION OF RESULTS

CALCULATIONS

1. Subtract the absorbance value of the reagent blank well from the absorbance values obtained in standard, control, and patient sample wells. Calculate the mean absorbance values for duplicate wells.
2. Plot the mean absorbance value of each calibrator serum 1 through 4 on the RELISA® Calibrator Curve Worksheet using the Blank Adjusted O.D. for the y-axis and the labeled IU/ml value for the x-axis. Draw a best fit line between the calibrator points.
3. Obtain the IU/ml value of each patient sample by interpolating from the Calibrator Curve.
4. If using a software program, use a 4-parameter fit with lin-log coordinates for optical density and concentration, and a best-fit curve.

OPTIONAL SINGLE POINT CALIBRATION METHOD

1. Subtract the absorbance value of the reagent blank well from the absorbance values obtained in calibrator, control, and patient sample wells. Calculate the mean absorbance values for duplicate wells.
2. Divide the specific antibody concentration in IU/ml of the #3 Calibrator (stated on the label) by the mean absorbance value of the calibrator wells to obtain the Conversion Factor.
3. Multiply the absorbance values of each of the samples by the Conversion Factor to obtain the specific antibody concentration in IU/ml.

4. The simplified form of these calculations can be expressed as:

$$\frac{\text{\#3 Calibrator Value (IU/ml)}}{\text{Absorbance of \#3 Calibrator}} \times \text{Absorbance of Sample}^* = \text{IU/ml Value for Sample}$$

*If calibrators and samples are run in duplicate, use the average absorbance of the duplicate wells.

QUALITY CONTROL

1. The mean absorbance value of the #3 Calibrator must be at least 0.400. Absorbance values less than 0.400 indicate inadequate color development, and an invalid run. Inadequate color development is usually due to use of cold reagents or incorrect timing of one or more steps of the assay. Allow reagents to warm to room temperature (18-25°C), and repeat the run with particular attention paid to the timing of all steps.
2. The blank control well should have an absorbance value of less than 0.150. Blank absorbance values greater than 0.150 indicate inadequate washing or contamination of reagents, and an invalid run.
3. The anti-dsDNA antibody values that are obtained for the positive control should be within the range indicated on the label. This range was established to encompass 95% of the values expected due to statistically normal variation. Occasional small deviations outside these ranges are expected. Each laboratory should establish its own accept/reject criteria based on its experience with this assay.
4. Samples with specific antibody values greater than the upper limit of the #3 Calibrator should be reported as greater than the unit value of the #3 Calibrator.
5. The Calibrator Curve must be plotted for each run (or the Conversion Factor must be calculated for each run if you are using the optional single point calibration). Using a Calibrator Curve or Conversion Factor from another run will invalidate the results.
6. Each laboratory should establish and maintain its own reference (normal) range values, based on the patient population and other local factors.
7. The positive control serum is a human serum that contains antibodies to dsDNA. This is a qualitative control that should give a value of greater than 35 IU/ml.
8. The negative control serum is a pool of human serum that does not contain antibodies to dsDNA. This control should give values of less than 35 IU/ml.

INTERPRETATION OF PATIENT RESULTS

The levels of antibodies to dsDNA have been shown to rise and fall with the course of disease, but the clinical significance of a single antibody level is still under study (13). The unit values obtained in this assay are designed merely to separate patients into the following broad groups. Patient sample wells that have calculated values greater than or equal to 35 IU/ml are considered to be positive. Patient sample wells that have calculated values less than 35 IU/ml are considered to be negative. Each laboratory must establish its own reference range and cut-off values based on the population of patients that are being tested. Unit values are affected by patient factors, mechanical considerations (such as pipetting precision and accuracy), and assay conditions (such as temperature and timing of steps.) Serial determinations of antibody levels on a patient may indicate the rise or fall of antibody levels.

REPORTING OF RESULTS

Results should be reported as positive or negative for antibodies to dsDNA, with the IU/ml value. The levels of antibodies found in a single sample have limited clinical significance. Serial determinations of antibody levels on a patient may indicate the rise or fall of antibody levels, which have been shown to follow disease course (13).

LIMITATIONS OF THE TEST

1. Diagnosis cannot be made on the basis of anti-dsDNA antibody detection alone. The physician must interpret these results in conjunction with the patient's history and symptoms, the physical findings, and other diagnostic procedures.
2. Treatment should not be initiated on the sole basis of a positive test for anti-dsDNA antibodies. Clinical indications, other laboratory findings, and the physician's clinical impression must be considered before any treatment is initiated.
3. Certain drugs, including procainamide and hydralazine, may induce a lupus erythematosus-like disease. Patients with drug-induced LE may demonstrate positive ANAs commonly directed against nuclear histones, although antibody to dsDNA has also been reported (9-10, 14).
4. Although a high level anti-dsDNA may be highly suggestive of SLE, it should not be considered diagnostic but rather viewed as a part of the overall clinical history of a patient. Low levels of dsDNA antibodies are often present in the sera of patients with rheumatoid arthritis, Sjögren's syndrome, progressive systemic sclerosis, dermatomyositis, discoid lupus erythematosus, and mixed connective tissue disease (2).
5. Patients undergoing steroid therapy may have negative results for dsDNA antibody (11).
6. The results of this test should be used in conjunction with information available from the clinical evaluation and other diagnostic procedures to determine the patient's clinical status.

EXPECTED VALUES

The expected value in the normal population is negative (less than 35 IU/ml). In patients with systemic lupus, up to 70% may show anti-dsDNA antibodies (15). Certain drugs may induce dsDNA antibody production (14).

PERFORMANCE CHARACTERISTICS

The Immuno Concepts RELISA[®] anti-dsDNA Test System was compared to another IgG anti-dsDNA EIA test system that is in commercial distribution. The population studied consisted of 108 samples that were positive for dsDNA and 100 normal blood donor samples that were tested in parallel on the predicate device and the subject device. Based on this comparison, the following data were obtained using the multi-point calibration method:

		Predicate IgG anti-dsDNA Test	
		Positive	Negative
Immuno Concepts RELISA [®] anti-dsDNA	Positive	105	6
	Negative	3	94

These data yield the following statistics: positive agreement, 97.2%; negative agreement, 94.0%; and overall agreement, 95.7%.

Based on this comparison, the following data were obtained using the optional single-point calibration method:

		Predicate IgG anti-dsDNA Test	
		Positive	Negative
Immuno Concepts RELISA [®] anti-dsDNA	Positive	103	5
	Negative	5	95

These data yield the following statistics: positive agreement, 95.4%; negative agreement, 95.0%; and overall agreement, 95.2%.

Normal Range: The normal range for this assay was determined by testing serum specimens from 261 healthy blood donors. Only two of these samples had values greater than 35 IU/ml for anti-dsDNA antibodies.

CLINICAL SPECIFICITY

The Immuno Concepts RELISA[®] anti-dsDNA Test System was used to test serum samples from 117 patients who were seen for rheumatological consult. This patient population was selected because of clinical rheumatic diseases, but not for any specific disease state. In this population, four samples (3.4%) were positive for anti-dsDNA antibodies.

CLINICAL SENSITIVITY

Serum specimens from thirty-nine patients with SLE were tested in the Immuno Concepts RELISA[®] anti-dsDNA Test System. Eight (20.5%) of these samples were positive for anti-dsDNA antibodies.

REPRODUCIBILITY

The precision of the assay was measured using three samples that had anti-dsDNA values in the linear portion of the calibration curve. These samples were run 20 times on three different lot numbers of antigen coated microwell strips in one test event by one technologist. The intra-assay and inter-assay precision is shown in the following Tables:

INTRA-ASSAY PRECISION

n=20	Mean (IU/ml)	S.D.	%C.V.
Sample 1	610	14	2
Sample 2	315	14	5
Sample 3	114	10	9

INTER-ASSAY PRECISION

n=60	Mean (IU/ml)	S.D.	%C.V.
Sample 1	601	24	4
Sample 2	329	16	5
Sample 3	122	11	9

VALIDATION OF SINGLE POINT CALIBRATION

The use of a single point calibrator was validated using the same panel of 108 positive sera that were used for comparison to the predicate device. Regression analysis of this comparison showed a regression coefficient (r^2) of 97.95%. From a practical point of view, in this comparison we saw only three samples (2.7%) that showed diagnostic discrepancies between the four-point calibration system and the optional single-point calibration system. All of these samples had anti-dsDNA IU/ml values close to the cutoff of 35 IU/ml, ranging from 33 to 40 IU/ml. This type of sample is a diagnostic problem in any assay system, and needs to be considered carefully by the laboratory professionals who analyze the samples and interpret the data.

CROSSREACTIVITY STUDIES

A total of 11 sera that contained autoantibodies including Sm, RNP, SSA, SSB, Scl-70 and Jo-1 were tested using the Immuno Concepts RELISA[®] anti-dsDNA Test System. None of these samples produced a positive result in the Immuno Concepts RELISA[®] anti-dsDNA Test System.

BIBLIOGRAPHY

1. Nakamura, R. M., Greenwald, C. A., Peebles, C. L., et al. Autoantibodies to Nuclear Antigens (ANA): Immunochemical Specificities and Significance in Systemic Rheumatic Disease. Chicago, American Society of Clinical Pathologists, 1978.
2. Notman, D.D., Kurata, N., Tan, E.M. Profiles of Antinuclear Antibodies in Systemic Rheumatic Diseases. Ann. Int. Med. 83:464-469, 1975.
3. Stingl, G., Meingassner, J. G., Swelty, P., et al. An Immunofluorescence Procedure for the Demonstration of Antibodies to Native, Double-Stranded DNA and of Circulating DNA-Anti-DNA Complexes. Clin. Immunol. Immunopathol. 6:131-140, 1976.
4. Edmonds, J. P., Johnson, G. D., Ansell, B.M., et al. The Value of Tests for Antibodies to DNA in Monitoring the Clinical Course of Systemic Lupus Erythematosus. A Long Term Study Using the Farr Test and the DNA Counterimmunoelectrophoretic Method. Clin. Exp. Immunol. 22:9-15, 1975.
5. Wold, R. T., Young, F. E., Tan, E. M., et al. Deoxyribonucleic Acid Antibody: A Method to Detect its Primary Interaction With Deoxyribonucleic Acid. Science 161:806-807, 1968.
6. Ginsberg, B., Keiser, H. A Millipore Filter Assay for Antibodies to Native DNA in Sera of Patients with Systemic Lupus Erythematosus. Arthritis Rheum. 16:199-207, 1973.
7. Schur, P. H., DeAngelis, D., Jackson, J. M. Immunological Detection of Nucleic Acids and Antibodies to Nucleic Acids and Nuclear Antigens by Counterimmunoelectrophoresis. Clin. Exp. Immunol. 17:209-218, 1974.
8. Crowe, W., Kushner, I. An Immunofluorescent Method using *Crithidia luciliae* to Detect Antibodies to Double Stranded DNA. Arth. Rheum. 20:811-814, 1977.
9. Epstein, W. V. Specificity of SLE Serum Antibody for Single-Stranded and Double-Stranded DNA Configuration. J. Rheum. 2:215-220, 1975.
10. Alarcon-Segovia, D., Fishbein, E. Patterns of Antinuclear Antibodies and Lupus-Activating Drugs. J. Rheum. 2:167-171, 1975.
11. Ballou, S.P., Kushner, I. Anti-Native DNA Detection by the *Crithidia luciliae* Method. Arthritis Rheum. 22:321-328, 1979.
12. Data on file, Immuno Concepts, N.A., Ltd.
13. Kavanaugh, A.F., Solomon, D.H., et al. Guidelines for Immunologic Laboratory Testing in the Rheumatic Diseases: Anti-DNA Antibody Tests. Arthritis Care Res. 47:546-555, 2002.
14. Vedove, C.D., Giglio, M.D., Schena, D., et al. Drug-induced Lupus Erythematosus. Arch. Dermatol. Res. 301:99-105, 2009.
15. Egner, W. The use of laboratory tests in the diagnosis of SLE. J. Clin. Pathol. 53:424-432, 2000.

In the event of damage to the protective packaging, please contact Immuno Concepts prior to use.



Manufacturer



Authorized Representative in the European Community



Temperature Limitation



Contains Sufficient for <n> tests



Consult Instructions for Use



In Vitro Diagnostic Medical Device



MDSS GmbH
Schiffgraben 41
D-30175 Hannover, Germany



Immuno Concepts, N.A. Ltd. 9825 Goethe Road, Suite 350 Sacramento, CA. 95827
Technical Support USA: 1.800.251.5115 Outside USA: 1.916.363.2649
Email: technicalsupport@immunoconcepts.com

RELISA® ANTI-DSDNA TEST PROCEDURE

All samples, reagents (including the wash buffer solution), and microwells must be at room temperature before use.

- 1. PREPARE WORKSHEET**

Label the worksheet that is enclosed in the kit to indicate the location of the samples in the microwells. Assay the calibrators in duplicate. To use the multi-point curve, all four calibrator sera must be run. For the optional single point calibration method, run only the #3 Calibrator serum in duplicate. One well is used for a reagent blank. We recommend that each control and patient sample be assayed in duplicate until an acceptable precision for the assay has been established in your laboratory.
- 2. PREPARE WASH BUFFER SOLUTION (PBS-Tween)**

Dissolve contents of one PBS buffer pouch in one liter of deionized or distilled water. Add the entire contents of one bottle of Wash Buffer Concentrate to the one-liter container of dissolved PBS. Mix well. The wash buffer solution may be covered and stored at 2-25°C up to four weeks.
- 3. DILUTE PATIENT SAMPLES**

Dilute patient samples 1:40 by adding 25 µl of serum to 975 µl of Sample Diluent. Mix well. The calibrator, positive control, and negative control are provided at the working dilution and do not require any further dilution.
- 4. PREPARE MICROWELLS**

Remove the required number of microwell strips from the pouch and place them in the frame holder. The microwells must be firmly seated in the frame holder. Press down firmly on both ends of the strips so that they securely snap into the frame holder. If using individual wells or less than a full strip of wells, be sure each well is firmly seated. Wells that are properly seated in the frame holder will not fall out when the frame holder is inverted. If fewer than eight wells are needed for testing, the wells can be separated by snapping them apart. Unused wells can be returned to the foil pouch, sealed with the zipper seal, and refrigerated for up to 45 days.
- 5. DISPENSE SERUM DILUTIONS**

Dispense 100 µl of the calibrators, controls, and diluted patient samples into the appropriate wells as outlined on the worksheet. Dispense 100 µl of Sample Diluent into the reagent blank well.
- 6. INCUBATE STRIPS (30 minutes at room temperature, i.e. 18-25°C)**

Incubate at room temperature for 30 minutes. The strips should be protected from drafts or shifts in temperature during incubation. If desired, the strips can be covered with transparent tape or a paper towel to protect them from dust or other foreign bodies.
- 7. WASH STRIPS (See General Procedural Notes 5 and 6)**

Wash the wells 3 to 5 times with PBS-Tween Wash Buffer Solution. For manual washing, aspirate the contents of the wells, then fill each well with wash buffer solution. Avoid cross-contamination of the wells, particularly in the first wash after aspiration. Drain all of the wash buffer from the wells by inverting, then shaking residual wash buffer from the wells with a sharp "snapping" motion of the wrist. Repeat the filling and draining steps for a total of 3 to 5 washes. The wells should then be rapped vigorously on a paper towel or other absorbent material to remove all traces of residual wash buffer.
- 8. DISPENSE ENZYME ANTIBODY REAGENT**

Dispense 100 µl of Enzyme Antibody Reagent to each of the wells.
- 9. INCUBATE STRIPS (30 minutes at room temperature, i.e., 18-25°C)**

Incubate at room temperature for 30 minutes. The strips should be protected from drafts or shifts in temperature during incubation. If desired, the strips can be covered with transparent tape or a paper towel to protect them from dust or other foreign bodies.
- 10. WASH STRIPS**

Wash the wells 3 to 5 times with PBS-Tween Wash Buffer Solution. For manual washing, aspirate the contents of the wells, then fill each well with wash buffer solution. Avoid cross-contamination of the wells, particularly in the first wash after aspiration. Drain all of the wash buffer from the wells by inverting, then shaking residual wash buffer from the wells with a sharp "snapping" motion of the wrist. Repeat the filling and draining steps for a total of 3 to 5 washes. The wells should then be rapped vigorously on a paper towel or other absorbent material to remove all traces of residual wash buffer.
- 11. DISPENSE SUBSTRATE SOLUTION**

Using a timer to assure consistent intervals, dispense 100 µl of Substrate Solution to each of the wells. The Substrate Solution must be added to the wells at a steady rate, so that each well is incubated for exactly the same length of time (30 minutes). The substrate solution in wells incubated with positive samples will turn blue, and the solution in wells incubated with negative samples will be colorless to very pale blue.
- 12. INCUBATE STRIPS (Exactly 30 minutes at room temperature, i.e., 18-25°C)**

Incubate at room temperature for exactly 30 minutes. The strips should be protected from drafts or shifts in temperature during incubation.
- 13. DISPENSE STOPPING REAGENT**

After the first well has incubated for exactly 30 minutes, add 100 µl of Stopping Reagent to each well, in the same order and at the same rate that the Substrate Solution was added to the wells. Upon addition of stopping reagent, blue substrate solution will turn yellow and colorless solution will remain colorless.
- 14. READ ABSORBANCE OF WELLS**

Within 30 minutes after addition of the stopping reagent, the wells must be read in a plate reading spectrophotometer. The wells are read at 450 nm against the blank control well. If a dual wavelength spectrophotometer is available, the wavelength for the reference filter should be set at 600-650 nm. Reading the microwells at 450 nm without a reference filter will result in higher absorbance values.

FOR TECHNICAL ASSISTANCE:

USA: 1-800-251-5115 Outside USA: 1-916-363-2649
Email: technicalsupport@immunoconcepts.com

